RANBAXY TO MARKET SEIZURE-CONTROL DRUG IN U.S.

India-based Ranbaxy will market Zonisamide capsules for the treatment of epilepsy in the U.S. through a partnership with Invagen Pharmaceuticals, the company announced. Zonisamide, indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy, is the generic equivalent of Eisai Pharmaceutical's Zonegran.

The agreement with Invagen provides for products to be developed and submitted to the FDA for approval. Ranbaxy will commercialize the product.

"The addition of Zonisamide … to our product mix through an alliance with Invagen reinforces our strategy to use inorganic means to grow our product pipeline, as well. Such partnerships with companies like Invagen, who have capabilities and competencies to develop bioequivalent generic products for the marketplace, are naturally beneficial to both organizations, while having a positive economic impact on the U.S. healthcare system," said Atul Malhotra, president of Ranbaxy.